

Nopol-Based Quinoline Derivatives as Antiplasmodial Agents

Rogers J. Nyamwihura, Huaisheng Zhang, Jasmine T. Collins, Olamide Crown, Ifedayo Victor Ogungbe*

Department of Chemistry, Physics, and Atmospheric Sciences, Jackson State University, Jackson, MS, 39217, USA

* Correspondence: ifedayo.v.ogungbe@jsums.edu; Tel.: +1-601-979-3719

Supplementary NMR and High-Resolution Mass Spectrometry (HRMS) Data




Figure 1.1a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-(6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(5-methoxyquinolin-8-yl) acetamide (**1**) in CDCl₃.




Figure 1.1b: HRMS: $[M+H]^+$: 337.1910 m/z for 2-(6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(5-methoxyquinolin-8-yl) acetamide (**1**).




Figure 1.2a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-(6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(5-methoxyquinolin-8-yl) acetamide (**2**) in CDCl₃.




Figure 1.2b: HRMS: $[M+H]^+$: 337.1916 m/z for 2-(6, 6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(5-methoxyquinolin-8-yl) acetamide (**2**).




Figure 1.3a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-(6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(quinolin-8-yl) acetamide (**3**) in CDCl₃.





Figure 1.3b: HRMS: $[M+H]^+$: 307.1804 m/z for 2-(6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(quinolin-8-yl) acetamide (**3**).






Figure 1.4b: HRMS: $[M+H]^+$: 307.1803 m/z for 2-(6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-N-(quinolin-8-yl) acetamide (**4**).




Figure 1.5a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-((1*S*,5*R*)-6,6-dimethylbicyclo[3.1.1] hept-2-en-2-yl)-*N*-(quinolin-4-yl) acetamide (**5**) in CDCl₃.





Figure 1.5b: HRMS: $[M-H]^-$: 305.1655 m/z for 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl)-*N*-(quinolin-4-yl) acetamide (**5**).







Figure 1.6b: HRMS: $[M-H]^-$: 339.1263 m/z for *N*-(7-chloroquinolin-4-yl)-2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetamide (**6**).






Figure 1.7b: HRMS: $[M+H]^+$: 308.1651 m/z for quinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**7**).




Figure 1.8a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 7-chloroquinolin-4-yl 2-((1S,5R)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**8**) in (CD₃)₂CO.




Figure 1.8b: HRMS $[M+H]^+$: 342.1259 m/z for 7-chloroquinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**8**).




Figure 1.9a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 7-chloro-2,8-dimethylquinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**9**) in (CD₃)₂CO.




Figure 1.9b: HRMS: $[M+H]^+$: 370.1574 m/z for 7-chloro-2,8-dimethylquinolin-4-yl 2-((1S,5R)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**9**).




Figure 1.10a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 6-fluoro-2-(trifluoromethyl)quinolin-4-yl 2-((1S,5R)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**10**) in CDCl₃.




Figure 1.10b: HRMS: $[M+Na]^+$: 416.1245 m/z for 6-fluoro-2-(trifluoromethyl) quinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) (**10**).




Figure 1.11: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 7-chloro-8-methylquinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**11**) in CDCl₃.




Figure 1.11b: HRMS: $[M+Na]^+$: 378.1234 m/z for 7-chloro-8-methylquinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**11**).




Figure 1.12a: (Top) ^1H -NMR and (Bottom) ^{13}C -NMR of 2,8 bis (trifluoromethyl)quinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**12**) in CDCl_3 .




Figure 1.12b: HRMS: $[M+Na]^+$: 466.1220 m/z for 8-bis(trifluoromethyl)quinolin-4-yl 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) acetate (**12**).




Figure 1.13a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-((1*S*,5*R*)-6,6-dimethylbicyclo[3.1.1] hept-2-en-2-yl) ethyl 7-chloro-2-methylquinoline-4-carboxylate (**13**) in CDCl₃.




Figure 1.13b: HRMS: $[M+H]^+$: 370.1575 m/z for 2-((1*S*,5*R*)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) ethyl 7-chloro-2-methylquinoline-4-carboxylate (**13**).




Figure 1.14a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-((1S,5R)-6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) ethyl 2-chloroquinoline-3-carboxylate (**14**) in CD₃OD.




Figure 1.14b: HRMS: $[M+H]^+$: 356.1417 m/z for 2-((1*R*, 5*S*)-6, 6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) ethyl 2-chloroquinoline-3-carboxylate (**14**).





Figure 1.15a: (Top) ¹H-NMR and (Bottom) ¹³C-NMR of 2-((1*R*,5*S*)-6,6-dimethylbicyclo[3.1.1] hept-2-en-2-yl) ethyl 1*H*-indole-2-carboxylate (15) in MeOD.




Figure 1.15b: HRMS: $[M+H]^+$: 310.1806 m/z for 2-((1*R*, 5*S*)-6, 6-dimethylbicyclo [3.1.1] hept-2-en-2-yl) ethyl 1*H*-indole-2-carboxylate (**15**).




Figure 1.16a: (Top) ^1H -NMR and (Bottom) ^{13}C -NMR of 2-((1*S*,2*S*,4*R*,6*S*)-7,7-dimethyl-3-oxatricyclo [4.1.1.0^{2,4}] octan-2-yl) ethyl-7-chloro-2 methylquinoline-4-carboxylate (**16**) in CDCl₃.




Figure 1.16b: HRMS: $[M+H]^+$: 386.1525 m/z for 2-((1*S*,2*S*,4*R*,6*S*)-7,7-dimethyl-3-oxatricyclo [4.1.1.0^{2,4}] octan-2-yl) ethyl 7-chloro-2-methylquinoline-4-carboxylate (**16**).